HLA-B27
Sign in to save{| id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border=0 cellpadding=0 align="right" width="240px" |- align="center" | colspan="3" | thumb|HLA-B*2705-peptide (chain A shown in green cartoon, chain B shown in yellow cartoon) complexed to a fragment of the influenza nucleoprotein NP383-391 (orange, sticks). PDB ID 2BST |- style="text-align: center; line-height: 0.75;background:#eeeeee" | colspan="3" color="white" | B*2705-β2MG with bound peptide |- style="text-align: center; line-height: 1.00;background:#eeeeee" | colspan="
Research
6,965 papers- HLA-B27.Annual review of immunology · 2015
- HLA-B27 and host-pathogen interaction.Advances in experimental medicine and biology · 2009
- HLA-B27 misfolding and spondyloarthropathies.Advances in experimental medicine and biology · 2009
- HLA-B27: what's new?Rheumatology (Oxford, England) · 2010
- Intestinal Microbiota, HLA-B27, and Spondyloarthritis: Dangerous Liaisons.Rheumatic diseases clinics of North America · 2020
via PubMed
Article
9 sectionsContents
- Prevalence
- Disease associations
- Pathological mechanism
- Antigen-dependent theories
- Antigen-independent theories
- HIV long-term nonprogressors
- See also
- References
- External links
{| id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border=0 cellpadding=0 align="right" width="240px" |- align="center" | colspan="3" | thumb|HLA-B*2705-peptide (chain A shown in green cartoon, chain B shown in yellow cartoon) complexed to a fragment of the influenza nucleoprotein NP383-391 (orange, sticks). PDB ID 2BST |- style="text-align: center; line-height: 0.75;background:#eeeeee" | colspan="3" color="white" | B*2705-β2MG with bound peptide |- style="text-align: center; line-height: 1.00;background:#eeeeee" | colspan="3" color="white" | |- | align="center" colspan="3" | |- style="text-align: center; line-height: 1.00;background:#eeeeee" | colspan="3" color="white" | |- | align="center" colspan="3" | |- | align="center" colspan="3" | major histocompatibility complex (human), class I, B27 |- | bgcolor="#e7dcc3" | Alleles | colspan = 2 bgcolor="#eeeeee" | B*2701, 2702, 2703, . . . |- align="center" | colspan="2" bgcolor="#dddddd" | Structure (See HLA-B) || bgcolor="#f4f4f4" |Available3D structures |- align="center" | rowspan=7 bgcolor="#e7dcc3" | EBI-HLA | bgcolor="#eeeeee" | B*2701 |- align="center" | bgcolor="#eeeeee" | B*2702 |- align="center" | bgcolor="#eeeeee" | B*2703 |- align="center" | bgcolor="#eeeeee" | B*2704 |- align="center" | bgcolor="#eeeeee" | B*2705 | , ,, ,, , , , , |- align="center" | bgcolor="#eeeeee" | B*2706 |- align="center" | bgcolor="#eeeeee" | B*2709 |, , , |- align="center" |}
Human leukocyte antigen (HLA) B27 (subtypes B*2701-2759) is a class I surface molecule encoded by the B locus in the major histocompatibility complex (MHC) on chromosome 6 and presents antigenic peptides (derived from self and non-self antigens) to T cells. HLA-B27 is strongly associated with ankylosing spondylitis and other associated inflammatory diseases, such as psoriatic arthritis, inflammatory bowel disease, and reactive arthritis.